Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:46:19 EDT Sun 19 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:RPTX from 2023-05-18 to 2024-05-17 - 31 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-05-07 16:49
U
U:RPTX
SEDAR Interim Financial Statements
812
SEDAR Interim MD & A
2024-05-07 16:05
U
U:RPTX
News Release
200
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
2024-04-30 07:05
U
U:RPTX
News Release
200
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
2024-04-30 07:05
U
U:RPTX
News Release
200
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
2024-04-26 16:05
U
U:RPTX
News Release
200
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
2024-02-29 07:05
U
U:RPTX
News Release
200
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
2024-02-28 15:58
U
U:RPTX
SEDAR Annual Information Form
802
SEDAR Annual Report
2024-02-28 15:01
U
U:RPTX
SEDAR Audited Annual Financial Statements
804
SEDAR MD & A
2024-02-28 07:05
U
U:RPTX
News Release
200
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-15 07:05
U
U:RPTX
News Release
200
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
2024-02-12 16:05
U
U:RPTX
News Release
200
Repare Therapeutics to Regain Global Rights to Camonsertib
2024-01-25 07:00
U
U:RPTX
News Release
200
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
2024-01-08 07:00
U
U:RPTX
News Release
200
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
2024-01-04 16:05
U
U:RPTX
News Release
200
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
2023-12-29 16:05
U
U:RPTX
News Release
200
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
2023-11-15 07:00
U
U:RPTX
News Release
200
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Ž ¸ Inhibitor
2023-11-09 11:30
U
U:RPTX
SEDAR Interim MD & A
813
SEDAR Interim MD & A
2023-11-09 11:28
U
U:RPTX
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2023-11-09 07:00
U
U:RPTX
News Release
200
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-07 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
2023-10-13 09:40
U
U:RPTX
News Release
200
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
2023-10-03 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-09-19 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-09-06 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-09 16:54
U
U:RPTX
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2023-08-09 16:05
U
U:RPTX
News Release
200
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-06-08 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-07 16:05
U
U:RPTX
News Release
200
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
2023-06-06 07:00
U
U:RPTX
News Release
200
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
2023-06-02 07:00
U
U:RPTX
News Release
200
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
2023-05-22 07:00
U
U:RPTX
News Release
200
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)